Key Takeaways HRMY shares dropped 16.56% after ZYN002 missed its main goal in the RECONNECT Fragile X study.Wakix generated $200.5M in Q2, with new phase III trials set to begin in narcolepsy and hypersomnia.HRMY expanded into rare epilepsy via Epygenix buyout, adding EPX-100 and EPX-200 to its pipeline.Shares of Harmony Biosciences Holdings, Inc. (HRMY) lost 16.56% on Sept. 24 after the company announced the failure of the late-stage registrational RECONNECT study on pipeline candidate ZYN002 in Fragile X ...

Accessibility StatementSkip Navigation 20 abstracts presented across World Sleep and Psych Congresses showcase Jazz's leadership in sleep medicine DUBLIN, Sept. 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced new real-world evidence and Phase 4 data reinforcing the value of Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution treatment outcomes in adults with narcolepsy or idiopathic hypersomnia (IH) were presented at World Sleep 2025, held in Singa ...